Menu
Washingtoner
  • Home
  • Technology
  • Boeing
  • Non-profit
  • Financial
  • Aerospace
  • Daryl Guberman
  • Business
  • Services
Washingtoner

FreezeNit Announces Exclusive Licensing of Novel Non-Toxic Lice Treatment Technology
Washingtoner/10287890

Trending...
  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
  • Spokane: Call for High School Artists: 2026 Riverfront Park Poster Contest
  • State of TBM 2025 Report: 83% of Organizations Boost Performance & Efficiency
FreezeNit
Naturally-Derived OTC Gel Eliminates Lice Without Neurotoxins, Launching Spring 2025

MARBLEHEAD, Mass. - Washingtoner -- FreezeNit, a leader in innovative lice treatment solutions, is thrilled to announce the exclusive licensing of a novel over-the-counter (OTC) lice treatment gel designed to provide a safe, naturally-derived, and highly effective alternative to traditional synthetic or pesticide-based lice treatments.

Unlike conventional OTC lice treatments that rely on pesticide-based pyrethroids, which have decreasing efficacy due to lice resistance, this new technology works by a purely mechanical method of action to eliminate lice and their eggs. The patented formula is free from harsh chemicals and instead leverages natural abrasives, such as diatomaceous earth and walnut shell powder, orange oil extract, and conditioning agents to physically shred lice and nits, while being gentle on the hair and scalp.

This addition strengthens FreezeNit's growing product portfolio, reinforcing the company's mission to provide clean, effective, science-backed treatments that parents can trust.

"This is an incredibly exciting milestone for FreezeNit," said Joanna Shu, CEO of FreezeNit. "By securing exclusive rights to this novel technology, we're positioned to be on the cutting edge of first aid treatments that are gentle on kids. Traditional lice treatments have failed parents and kids, but with this gel, lice don't stand a chance."

More on Washingtoner
  • New Research Identifies "The Busy Effect": 89% of Americans Want a Laid-Back Vacation — Only 15% Actually Achieve It
  • Alchemy 43 Appoints Shane Smith as CEO to Drive Operational Performance and Scalable Growth
  • Best Spiritual Healing, Meditation & Retreats in Sedona — Rise Meditation Helps You Find and Book Transformational Experiences
  • City of Tacoma Recognized for 39th Consecutive Year with Highest Honor in Governmental Financial Reporting
  • Tacoma: City to Conduct Essential Asphalt Repairs on Proctor Street April 6 – 10

✔ Clinically Proven – was shown to be 96% effective in a clinical trial.
✔ No Resistance Issues – Unlike permethrin-based treatments, which have seen increased lice resistance, this technology works mechanically—not chemically—so lice cannot develop immunity.
✔ Patented & Protected – This novel formula and method of action is patented in the U.S., Canada, and the EU, ensuring exclusivity in the market.
✔ Class I, 510(k) Exempt – The FDA-regulated status allows for a fast-tracked market entry.

FreezeNit is actively engaging with retailers, distributors, and healthcare providers to bring this breakthrough lice treatment to families everywhere.

FreezeNit is an innovative healthcare company dedicated to revolutionizing first-aid with safe, effective, and science-backed solutions. By leveraging cutting-edge technology and natural alternatives to neurotoxins, FreezeNit provides families with fast, reliable, and pesticide-free treatments for head lice infestations.  For more information, visit www.FreezeNit.com.

Media Contact
Cathy Henry
cathy@freezenit.com
214-924-5992


Source: FreezeNit

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • UK Financial Ltd Chooses PUMP.FUN App to Launch Maya Meme's Minor-League Meme Coins and Announces Lifetime Airdrop Program
  • Suspect Arrested, Stolen Trailer and Property Recovered in Tacoma Vehicle Theft Investigation
  • Boston Industrial Solutions Expands Its Industry-Leading UV Ink Portfolio with the Launch of a Matte Ink - Natron® UVPZ
  • Century Fasteners Corp. Exhibiting at 2026 MRO Americas Show – April 21-23, 2026 – Booth #2257
  • Blue Sparrow Coffee named Best Matcha in Westword's Best of Denver 2026
  • Ocean County College Introduces Pathways to Simplify the Student Journey and Strengthen Career Connections
  • Kiko Nation Expands to Apple App Store, Achieving Full Mobile Deployment for Livestock Digital Registry Platform
  • The Lawyers' Marketer Launches Claude AI Implementation Service for Law Firms
  • Certified Trading Card Association and Collectors MD Launch Healthy Hobby Initiative
  • A Letter From the Tacoma City Council to the Sound Transit Board
  • Tacoma: City Council Approves Contract, Officially Appointing Hyun Kim as City Manager
  • Tacoma: Homicide Investigation – 3400 Block South 19th Street
  • L2 Aviation Earns FAA STC for Thales AVIATOR 200S for Boeing 777
  • Women-Owned Business Platform SmartPath Launches to Help Entrepreneurs Build with Confidence
  • FinIQ Edu Launches High-Impact Workshop Vertical to Close the Workplace Benefits Gap—Drives 82% Surge in 401(k) Participation Intent
  • HousingWire launches Mortgage Rankings, bringing a data-driven benchmark to originator performance
  • J&J Exterminating Reminds Residents to prepare for Termite Swarm Season
  • City of Spokane Celebrates Return of Spokane Gives
  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
  • Just 1 in 57 Crypto Owners Globally Pay Taxes on Their Holdings, New Report Finds
_catLbl0 _catLbl1

Popular on Washingtoner

  • Spokane: Indian Canyon Golf Course Opens Thursday, March 12, 2026
  • Independent Financial Agencies Upgrade City of Tacoma’s Bond Ratings Amid Broader Economic Uncertainty
  • ANAB's Fraud Taints AS9100, ISO 9001, ISO 13485 Certs (2018-Present) – Stop Paying Registrars
  • The Media Should Protect the Public When It Comes to Boeing — But Does It?
  • $167 Billion Pharma R&D Market Largely Untapped by AI Creates Major Growth Runway for KALA Bios Data-Sovereign AI Strategy: N A S D A Q: KALA
  • Pregis Expands Wind Energy Use, Advancing Progress Toward Net Zero by 2040
  • New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
  • Quadcode Acquires Significant Stake in Game 7, LLC - The Parent Company for FPFX Tech and PropAccount.com
  • Conexwest: Shipping Containers Are Powering the Next Generation of Bitcoin Mining Infrastructure
  • Yoga Retreats, Ecstatic Dance & Spiritual App launched

Similar on Washingtoner

  • Architect of Neurodiversity Will Lead the First U.S. Team of Autistic Children to the "Genius Cup" in Hiroshima, Japan, in 2027
  • Deborah E. Jones Introduces Emotional Sovereignty, a Powerful New Book on Emotional Mastery, Resilience, and Intentional Living
  • New Research Identifies "The Busy Effect": 89% of Americans Want a Laid-Back Vacation — Only 15% Actually Achieve It
  • Alchemy 43 Appoints Shane Smith as CEO to Drive Operational Performance and Scalable Growth
  • Best Spiritual Healing, Meditation & Retreats in Sedona — Rise Meditation Helps You Find and Book Transformational Experiences
  • Appliance EMT Named Among Jacksonville's Top 3 Appliance Repair Companies by ThreeBestRated®
  • Boston Industrial Solutions Expands Its Industry-Leading UV Ink Portfolio with the Launch of a Matte Ink - Natron® UVPZ
  • Blue Sparrow Coffee named Best Matcha in Westword's Best of Denver 2026
  • J&J Exterminating Reminds Residents to prepare for Termite Swarm Season
  • AI-Driven Breakthrough Unleashed: Bionic Intelligence Platform Goes Live to Capture Massive Biotech Opportunity: KALA BIO, Inc. (N A S D A Q: KALA)
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute